EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Gut microbial metabolite butyrate boosts p53-expressing telomerase-specific oncolytic adenovirus efficacy by enhancing infectivity and activating MHC-I/cGAS-STING

Masaki Sakamoto, Shinji Kuroda, Tetsuya Katayama, Yu Mikane, Shunya Hanzawa, Daisuke Kadowaki, Yusuke Yoshida, Yuki Hamada, Ryoma Sugimoto, Chiaki Yagi, Masashi Hashimoto, Nobuhiko Kanaya und 7 weitere

Cancer Immunology, Immunotherapy · 2025

DOI: 10.1007/s00262-025-04252-4 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Immunology, Immunotherapy, 2025. Verfasst von Masaki Sakamoto und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2-5-1 Shikata-cho, …. Hauptthemen laut MEDLINE: Oncolytic Virotherapy, Adenoviridae, Oncolytic Viruses, Butyrates. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science, Japan Agency for Medical Research and Development.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The gut microbiota plays an essential role in regulating host immunity, and its metabolites such as butyrate exert immunomodulatory effects by acting as histone deacetylase inhibitors. Oncolytic virotherapy has emerged as a promising approach for cancer treatment, and we have developed OBP-702, a telomerase-specific oncolytic adenovirus that expresses p53 and elicits strong systemic antitumor responses. In this study, the potential synergy between butyrate and OBP-702 was investigated in colorectal cancer models. Using human and murine colorectal carcinoma cell lines, butyrate was found to directly enhance the infectivity of OBP-702 by upregulating CAR and integrins, thereby promoting apoptosis and autophagy in tumor cells. In addition, butyrate indirectly boosted systemic antitumor immunity by upregulating MHC-I expression through activation of the cGAS-STING pathway and enhancing CD8 + T cell recruitment via CXCL10 secretion. These findings were supported by in vivo experiments using CT26 subcutaneous, bilateral, and orthotopic tumor models, in which the combination of oral butyrate and intratumoral OBP-702 administration produced synergistic antitumor effects. These results highlight the therapeutic potential of integrating gut microbial metabolites with oncolytic virotherapy as a novel immunotherapeutic strategy for colorectal cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Oncolytic VirotherapyAdenoviridaeOncolytic VirusesButyratesGastrointestinal MicrobiomeTumor Suppressor Protein p53TelomeraseMembrane ProteinsColorectal NeoplasmsHumansAnimalsMiceCell Line, TumorMice, Inbred BALB CHistocompatibility Antigens Class IXenograft Model Antitumor AssaysFemale

Stichwörter der Autor:innen

ButyrateCD8 + T cellsCancer immunotherapyMHC-IOncolytic adenovirus

Substanzen

ButyratesTumor Suppressor Protein p53TelomeraseMembrane ProteinsHistocompatibility Antigens Class I

Autor:innen und Institutionen

  • Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Kita-ku, Okayama, 700-8558, Japan.
  • Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Kita-ku, Okayama, 700-8558, Japan. shinkuro@okayama-u.ac.jp.
  • Center for Innovative Clinical Medicine, Okayama University Hospital, Okayama, Japan.
  • Oncolys BioPharma, Inc., Tokyo, Japan.

Förderung

  • Japan Society for the Promotion of Science
  • Japan Agency for Medical Research and Development

Zitieren

APA

Sakamoto, M., Kuroda, S., Katayama, T., Mikane, Y., Hanzawa, S., Kadowaki, D., Yoshida, Y., Hamada, Y., Sugimoto, R., Yagi, C., Hashimoto, M., Kanaya, N., Kakiuchi, Y., Kikuchi, S., Shigeyasu, K., Tazawa, H., Kagawa, S., Urata, Y., & Fujiwara, T. (2025). Gut microbial metabolite butyrate boosts p53-expressing telomerase-specific oncolytic adenovirus efficacy by enhancing infectivity and activating MHC-I/cGAS-STING. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-025-04252-4

Vancouver

Sakamoto M, Kuroda S, Katayama T, Mikane Y, Hanzawa S, Kadowaki D, et al. Gut microbial metabolite butyrate boosts p53-expressing telomerase-specific oncolytic adenovirus efficacy by enhancing infectivity and activating MHC-I/cGAS-STING. Cancer Immunology, Immunotherapy. 2025. doi:10.1007/s00262-025-04252-4

BibTeX
@article{Sakamoto2025,
  author = {Sakamoto, Masaki and Kuroda, Shinji and Katayama, Tetsuya and Mikane, Yu and Hanzawa, Shunya and Kadowaki, Daisuke and Yoshida, Yusuke and Hamada, Yuki and Sugimoto, Ryoma and Yagi, Chiaki and Hashimoto, Masashi and Kanaya, Nobuhiko and Kakiuchi, Yoshihiko and Kikuchi, Satoru and Shigeyasu, Kunitoshi and Tazawa, Hiroshi and Kagawa, Shunsuke and Urata, Yasuo and Fujiwara, Toshiyoshi},
  title = {Gut microbial metabolite butyrate boosts p53-expressing telomerase-specific oncolytic adenovirus efficacy by enhancing infectivity and activating MHC-I/cGAS-STING},
  journal = {Cancer Immunology, Immunotherapy},
  year = {2025},
  doi = {10.1007/s00262-025-04252-4}
}
Kostenlos starten →